NCT03432741 2025-05-26Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerMayo ClinicPhase 1 Terminated17 enrolled
NCT04431635 2024-09-27Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaUniversity of Michigan Rogel Cancer CenterPhase 1 Terminated6 enrolled
NCT04933617 2024-07-09Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Terminated8 enrolled 17 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT04156828 2023-06-29Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaUniversity of WashingtonPhase 1 Terminated12 enrolled
NCT03128619 2022-09-26Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerJonsson Comprehensive Cancer CenterPhase 1 Terminated10 enrolled